Prollenium Medical Technologies Inc. Reacquires Ovita® HV Brand for Global Distribution

AURORA, ON, June 24, 2013 /CNW/ - Prollenium Medical Technologies Inc. is proud to announce the reacquisition of the rights to Ovita® HV, a hyaluronic based dermal filler. Ovita® is a high viscosity, non-animal based, biodegradable gel that treats deep and more pronounced lines and wrinkles, particularly oral commissures and nasolabial folds. The brand is produced by Prollenium and will be distributed worldwide.

In 2010, Prollenium entered a partnership with international pharmaceutical company Valeant to supply and distribute Ovita® HV. After years of a successful relationship, the two companies have mutually ended the agreement putting Ovita® HV back in the hands of Prollenium. "The agreement with Valeant was very rewarding for Prollenium and Ovita® HV. The sales and marketing support Valeant dedicated to Ovita® HV has put the product in the forefront of customer's minds providing a great opportunity for us to sustain business going forward," says Prollenium's Senior Vice President Khasha Ighanian.

"Here at Prollenium, we commend Valeant for a job well done promoting the home grown aspect of Ovita® HV. We are very excited to confirm that the product will not be discontinued, but will in fact, continue to be produced in house at our facility in Aurora, Ontario, Canada," says Managing Director Ario Khoshbin. Ovita® HV is produced in the only dermal filler manufacturing facility for tissue reconstruction in Canada. The facility is also the home of the company's Sales, Marketing and R&D teams.

Prollenium is highly dedicated to the research of innovative products to provide to the marketplace. Reacquiring the rights to Ovita® HV presents the company with the opportunity to greatly expand this product line. A new addition, Ovita® HV with Lidocaine, a topical anesthetic, will be available in the Fall of 2013. In addition to dermal fillers, Prollenium extends its product offering into the skincare, revitalization and therapeutic markets worldwide.

For more information, please visit www.prollenium.com

Prollenium Medical Technologies Inc. is a Canadian-based company, founded in 2002, dedicated to the research, design, manufacture and distribution of implantable polymers in the pharmaceutical/dermatological industry. The company is committed to providing innovative products worldwide that are safe and viable. Flagship product lines include Revanesse®, Phiderma® and Rheo Vital™.

SOURCE: Prollenium Medical Technologies Inc.

Contact: Brittany Edwards
905.508.1469
[email protected]